196 related articles for article (PubMed ID: 17617631)
41. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
42. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines.
Colluru VT; McNeel DG
Oncotarget; 2016 Oct; 7(42):67901-67918. PubMed ID: 27661128
[TBL] [Abstract][Full Text] [Related]
43. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
44. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
45. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
[TBL] [Abstract][Full Text] [Related]
46. Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8
Booty MG; Hlavaty KA; Stockmann A; Ozay EI; Smith C; Tian L; How E; Subramanya D; Venkitaraman A; Yee C; Pryor O; Volk K; Blagovic K; Vicente-Suarez I; Yarar D; Myint M; Merino A; Chow J; Abdeljawad T; An H; Liu S; Mao S; Heimann M; Talarico L; Jacques MK; Chong E; Pomerance L; Gonzalez JT; von Andrian UH; Jensen KF; Langer R; Knoetgen H; Trumpfheller C; Umaña P; Bernstein H; Sharei A; Loughhead SM
J Immunol; 2022 Feb; 208(4):929-940. PubMed ID: 35091434
[TBL] [Abstract][Full Text] [Related]
47. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
48. Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation.
Lee SJ; Song L; Yang MC; Mao CP; Yang B; Yang A; Jeang J; Peng S; Wu TC; Hung CF
Vaccine; 2015 Mar; 33(13):1549-55. PubMed ID: 25701675
[TBL] [Abstract][Full Text] [Related]
49. T Cells as Antigen Carriers for Anti-tumor Vaccination.
Traversari C; Russo V
Methods Mol Biol; 2016; 1393():97-104. PubMed ID: 27033219
[TBL] [Abstract][Full Text] [Related]
50. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
51. Ag-bearing liposomes engrafted with peptides that interact with CD11c/CD18 induce potent Ag-specific and antitumor immunity.
Faham A; Altin JG
Int J Cancer; 2011 Sep; 129(6):1391-403. PubMed ID: 21128234
[TBL] [Abstract][Full Text] [Related]
52. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
[TBL] [Abstract][Full Text] [Related]
53. Vaccination as immunotherapy for B cell lymphoma.
Schultze JL
Hematol Oncol; 1997 Aug; 15(3):129-39. PubMed ID: 9600112
[TBL] [Abstract][Full Text] [Related]
54. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
Front Immunol; 2018; 9():822. PubMed ID: 29755461
[TBL] [Abstract][Full Text] [Related]
55. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
56. Vaccination with immature dendritic cells combined with CD40mAb induces protective immunity against B lymphoma in hu-SCID mice.
Ge Y; Xi H; Zhang XG
Biomed Pharmacother; 2010 Sep; 64(7):487-92. PubMed ID: 20382498
[TBL] [Abstract][Full Text] [Related]
57. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells.
Page G; Chevrel G; Miossec P
Arthritis Rheum; 2004 Jan; 50(1):199-208. PubMed ID: 14730617
[TBL] [Abstract][Full Text] [Related]
58. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
59. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes.
Rohrer JW; Barsoum AL; Dyess DL; Tucker JA; Coggin JH
J Immunol; 1999 Jun; 162(11):6880-92. PubMed ID: 10352310
[TBL] [Abstract][Full Text] [Related]
60. Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.
Gordy JT; Luo K; Francica B; Drake C; Markham RB
J Immunother; 2018 May; 41(4):181-189. PubMed ID: 29334492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
